CAIN SCHEXNEIDER: Open Payments
NPI 1588147276 · LAKE CHARLES, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$703 in 42 payments from 13 companies in 2025. Trend: 2023 $466 · 2024 $444 · 2025 $703
Food & beverage: $703
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $199 |
| Vanda Pharmaceuticals Inc. | 9 | $136 |
| Axsome Therapeutics, Inc. | 4 | $83 |
| Alkermes, Inc. | 3 | $55 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $52 |
| Supernus Pharmaceuticals, Inc. | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Janssen Pharmaceuticals, Inc | 1 | $23 |
| Corium, LLC | 1 | $20 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
Products named: VRAYLAR, FANAPT, Auvelity, ARISTADA, CAPLYTA, Qelbree, TRINTELLIX, SPRAVATO.
Industry payments across LA — which companies pay providers there.
